Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

The risk of varicella zoster virus infection in multiple sclerosis patients treated with fingolimod.
Differential effects of fingolimod on B-cell populations in multiple sclerosis.
[Intractable vomiting as first manifestation of neuromyelitis Optica.]
Pediatric multiple sclerosis.
Cause of death in MS: long-term follow-up of a randomised cohort, 21 years after the start of the pivotal IFNβ-1b study.
Immunomodulatory drugs (natalizumab), worsening of multiple sclerosis, rebound effect and similitude.
Microglia activation is associated with IFN-α induced depressive-like behavior.
Multiple sclerosis: presence of lymphatic capillaries and lymphoid tissue in the brain and spinal cord.
Impact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: a prospective, open-label, two years observational study.
GEMSP: A New Therapeutic Approach to Multiple Sclerosis.
Combination Treatment of Interferon β-1b and Warfarin for a Patient With Baló's Concentric Sclerosis and Antiphospholipid Syndrome.
Genzyme's Lemtrada resubmission accepted for review by FDA
CNS myelin wrapping is driven by actin disassembly.
Gut microbiota composition and relapse risk in pediatric MS: A pilot study.
Apitope Announces Positive Results from Clinical Trial of ATX-MS-1467 in Relapsing Multiple Sclerosis
Teva Presents Data Comparing Early Treatment with COPAXONE® 40 mg/mL to Delayed Start Treatment at 67th American Academy of Neurology (AAN) Annual Meeting in Washington, D.C.
IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H).
Monoclonal antibodies conjugated with superparamagnetic iron oxide particles allow magnetic resonance imaging detection of lymphocytes in the mouse brain.
Does interferon Beta-1a impact pure-tone hearing sensitivity among individuals with multiple sclerosis?
Simvastatin as add-on therapy to interferon β-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial.
Reactive astrocytes form scar-like perivascular barriers to leukocytes during adaptive immune inflammation of the CNS.
Glatiramer acetate does not protect from acute ischemic stroke in mice.
In vivo gene expression revealed by cDNA arrays: the pattern in relapsing-remitting multiple sclerosis patients compared with normal subjects.
Significant Percentage of MS Patients Receiving Alemtuzumab in Genzyme’s Phase 2 Trial Remain Free of Clinically Active Disease
Multiple associations between a broad spectrum of autoimmune diseases, chronic inflammatory diseases and cancer.

Pages